Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
Authors:
- 1 February 2023
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (4_suppl) , 708
Abstract
No abstract availableKeywords
Funding Information
- Seagen Inc.
- Merck Sharp & Dohme Corp